Clinical Trial Detail

NCT ID NCT02437370
Title Pembrolizumab and Docetaxel or Gemcitabine Hydrochloride in Treating Patients Urothelial Cancer
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors University of California, Davis
Indications

urethra transitional cell carcinoma

ureter transitional cell carcinoma

bladder urothelial carcinoma

renal pelvis transitional cell carcinoma

Therapies

Pembrolizumab

Gemcitabine

Docetaxel

Age Groups: adult

No variant requirements are available.